Will Ozempic Crush the Junk-Food Business?
As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.
Related Articles
Hematology & Medical Oncology Practice Updates and Board Review 2025 | Mayo Clinic School of Continuous Professional Development | CME Course Conference
February 3 – 7, 2025 – The Ritz Carlton Maui – Kapalua, Hawaii This course offers Live (in-person) and Livestream (virtual) attendance options. The Mayo…
Life expectancy gap in U.S. widens to 20 years due to “truly alarming” health disparities, researchers say
Life expectancy in the United States varies by more than 20 years depending on race and ethnicity and where you live, according to new research.
ISTH Podcasts
ISTH is the leading international professional society on thrombosis and hemostasis. Listen to our podcast for the latest educational resources in our field.
Frontiers | Late radiation-related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiation
1 Washington University School of Medicine in St. Louis, St. Louis, MO, United States 2 Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United…
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma – PubMed
In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment-decisions remains unclear. In a phase II…
New treatments offer hope for older patients with a deadly cancer diagnosis
Glioblastoma typically kills within 18 months, but a new type of treatment has kept Nadya El-Afandi’s scans clear 17 months after diagnosis.
Rising lung cancer cases in nonsmoking women under 50: Experts urge awareness
An unexpected surge in lung cancer cases among nonsmoking women under 50 is raising alarms among oncologists, emphasizing the need for heightened awareness.
AI-designed drug ISM5939 granted IND clearance for cancer clinical trials
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential…